Document Detail


Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema: a report by the American Academy of Ophthalmology.
MedLine Citation:
PMID:  22917890     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To review the evidence regarding the safety and efficacy of current anti-vascular endothelial growth factor (VEGF) pharmacotherapies for the treatment of diabetic macular edema (DME).
METHODS: Literature searches last were conducted in September 2011, in PubMed with no date restrictions, limited to articles published in English, and in the Cochrane Library without a language limitation. The combined searches yielded 532 citations, of which 45 were deemed clinically relevant for the authors to review in full text and to assign ratings of level of evidence to each of the selected studies with the guidance of the panel methodologists.
RESULTS: At this time, there are 5 studies that provide level I evidence for intravitreal ranibizumab, alone or in combination with other treatments for DME. There is also 1 study that provides level I evidence for intravitreal pegaptanib sodium for DME. Nine studies reviewed were rated as level II, and 2 additional studies reviewed were graded as level III. Most studies do not provide information about long-term results (i.e., more than 2 years of follow-up) or the comparative efficacy of anti-VEGF pharmacotherapies.
CONCLUSIONS: Review of the available literature indicates that anti-VEGF pharmacotherapy, delivered by intravitreal injection, is a safe and effective treatment over 2 years for DME. Further evidence is required to support the long-term safety of these pharmacotherapies and their comparative efficacy.
Authors:
Allen C Ho; Ingrid U Scott; Stephen J Kim; Gary C Brown; Melissa M Brown; Michael S Ip; Franco M Recchia
Publication Detail:
Type:  Journal Article; Review     Date:  2012-08-20
Journal Detail:
Title:  Ophthalmology     Volume:  119     ISSN:  1549-4713     ISO Abbreviation:  Ophthalmology     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-04     Completed Date:  2012-12-19     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  7802443     Medline TA:  Ophthalmology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2179-88     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
Affiliation:
American Academy of Ophthalmology, San Francisco, California, USA. ncollins@aao.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Academies and Institutes / organization & administration
Angiogenesis Inhibitors / administration & dosage*,  adverse effects
Antibodies, Monoclonal, Humanized / administration & dosage,  adverse effects
Aptamers, Nucleotide / administration & dosage,  adverse effects
Diabetic Retinopathy / drug therapy*
Humans
Intravitreal Injections
Macular Edema / drug therapy*
Ophthalmology / organization & administration
Recombinant Fusion Proteins / administration & dosage,  adverse effects
Technology Assessment, Biomedical
Treatment Outcome
United States
Vascular Endothelial Growth Factor A / antagonists & inhibitors*
Chemical
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal, Humanized; 0/Aptamers, Nucleotide; 0/Recombinant Fusion Proteins; 0/VEGFA protein, human; 0/Vascular Endothelial Growth Factor A; 0/pegaptanib; 0/ranibizumab; 15C2VL427D/aflibercept; 2S9ZZM9Q9V/bevacizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Resection of Intraocular Tumors (Partial Lamellar Sclerouvectomy) in the Pediatric Age Group.
Next Document:  Identification of an RP1 Prevalent Founder Mutation and Related Phenotype in Spanish Patients with E...